1 |
Fan, M., Bigsby, R. M., and Nephew, K. P. (2003). The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol. Endocrinol. 17,356-365
DOI
ScienceOn
|
2 |
Hur, E., Chang, K. Y., Lee, E., Lee, S. K. and Park, H. (2001). Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-lalpha. Mol. Pharmacal. 59, 1216-1224
DOI
|
3 |
Mazure, N. M., Chauvet, C., Bois-Joyeux, B., Bernard, M. A., Nacer-Cherif, H. and Danan, J. L. (2002). Repression of alphafetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res. 62, 1158-1165
|
4 |
McDonnell, D. P. and Norris, J. D. (2002). Connections and regulation of the human estrogen receptor. Science 296, 1642-1644
|
5 |
Nawaz, Z., Lonard, D. M., Dennis, A. P., Smith, C. L. and O'Malley, B. W. (1999). Proteasorne-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. USA 96, 18581862
|
6 |
Nawaz, Z. and O'Malley, B. W. (2004). Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription Mol. Endocrinol. 18, 493-499
|
7 |
Reid, G., Denger, S., Kos, M. and Gannon, F. (2002) Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cell Mol. Life Sci. 59, 821-831
DOI
ScienceOn
|
8 |
Shao, W. and Brown, M. (2004). Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 6, 39-52
DOI
ScienceOn
|
9 |
Semenza, G. L., Agani, F. Iyer, N. Jiang, B. H., Leung, S., Wiener, C. and Yu, A. (1998). Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology; Chest 114, 40S-45S
DOI
ScienceOn
|
10 |
Stoner, M., Saville, B., Wormke, M., Dean, D., Burghardt, R., and Safe, S. (2002). Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol. Endocrinol. 16,2231-2242
DOI
ScienceOn
|
11 |
Wormke, M., Stoner, M., Saville, B., Walker, K., Abdelrahim, M., Burghardt, R. and Safe, S. (2003). The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol. Cell Bioi. 23, 1843-1855
DOI
ScienceOn
|
12 |
Yan, S. F., Zou, Y S., Gao, Y, Zhai, c, Mackman, N., Lee, S. L., Milbrandt, J, Pinsky, D., Kisiel, W. and Stem, D. (1998). Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc. Natl. Acad. Sci. USA 95, 8298-8303
|
13 |
Cassoni, P., Catalano, M. G, Sapino, A., Marrocco, T., Fazzari, A., Bussolati, G and Fortunati, N. Oxytocin modulates estrogen receptor alpha expression and function in MCF7 human breast cancer cells. Int. J. Oncol. 21, 375-378 (2002)
|
14 |
Beato, M. and Klug, J. (2000). Steroid hormone receptors: an update. Hum. Reprod. Update. 6, 225-236
DOI
ScienceOn
|
15 |
Brahimi-Hom, C., Berra, E. and Pouyssegur, J. (2001). Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol. 11, S32-36
DOI
|
16 |
Gehm, B. D., McAndrews, J. M., Chien, P. Y., and Jameson, J., Resveratrol, L. (1997). A polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 94,14138-14143
|
17 |
Vincent, K. A., Shyu, K. G, Luo, Y, Magner, M., Tio, R. A., Jiang, C; Goldberg, M. A., Akita, G. Y, Gregory, R. J, and Isner, J. M. (2000). Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-Ialpha/ VP16 hybrid transcription factor. Circulation 102, 2255-2261
DOI
ScienceOn
|
18 |
Alarid, E. T., Bakopoulos, N. and Solodin, N. (1999). Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol. Endocrinol., 13, 1522-1534
DOI
ScienceOn
|
19 |
Alarid, E. T., Preisler-Mashek, M. T. and Solodin, N. M. (2003). Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endoerinol. 144, 3469-347
DOI
ScienceOn
|
20 |
Belanger, A. J., Lu, H., Date, T., Liu, L. X., Vincent, K. A., Akita, G Y., Cheng, S. H., Gregory, R. J., and Jiang, C. Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor lalpha. J. Mol. Cell Cardiol., 34, 765-774 (2002)
DOI
ScienceOn
|
21 |
Catherino, W. H., Wolf, D. M., and Jordan, V. C. (1995). A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol. Endocrinol., 9 1053-1063
DOI
|
22 |
Cicatiello, L. Addeo, R. Altucci, L. Belsito, V. Petrizzi, V. Boccia, M. Cancemi, D. Germano, C. Pacilio, S. Salzano, F. Bresciani, A. Weisz, L. Cicatiello, R. Addeo, L. Altucci, Belsito, Petrizzi, V. Boccia, V. Cancemi, M., Germano, D., Pacilio, C; Salzano, S., Bresciani, F, and Weisz, A. (2000). The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogenregulated processes required for cell cycle completion. Mol. Cell Endoerinol. 165, 199-209
DOI
ScienceOn
|
23 |
Khissiin, A., EI and Leclercq, G (1999). Implication of protea- some in estrogen receptor degradation. FEBS Lett. 448, 160-166
DOI
ScienceOn
|